KLK3 and Familial prostate cancer: A significant increase in overall survival (64% vs. 45%) in favor of ADT and also improvement in PSA recurrence free survival (53% vs. 14%) disease free survival (60% vs. 25%) and prostate cancer specific survival (85% vs. 51%) was observed.30